Dr. Furmanski’s background is in cancer molecular and cell biology, mechanisms of tumor progression, experimental therapeutics of cancer and other invasive/infectious processes, preclinical and human clinical trials. He has expertise in a number of areas, including pathogenesis of environmental toxin-induced disease, role of macrophages in inflammatory processes related to environmental exposures, health effects of nanoparticles, genetic and epigenetic regulation of cellular functions, among others. As a result of long service to the scientific community on a number of Editorial Boards, grant review committees, advisory boards, he is very active as a mentor for junior faculty and those newly moving into the field (as well as more senior members) in many aspects of the scientific and administrative process, including interactions with industry (big pharma, biotech, materials and devices).

Scholarly Activities

• Member and Inaugural Chair, Pathology C (Cancer Molecular Pathobiology/CAMP) Study Section, National Institutes of Health, June 2001 – October 2003
• Member, Advisory Committee for Oncologic Sciences, Center for Scientific Review, National Institutes of Health, January – June 1999 – June 2000
• Member, National Institutes of Health Reviewers Reserve, July 1993 – July 1998
• Member, Pathology B Study Section, Division of Research Grants, National Institutes of Health, October 1988 – June 1993
• Chairman, Cancer Biology and Immunology Contracts Review Committee, National Cancer                 Institute,   May 1985 – October 1987

Recent Publications

1. Kabeya, V, Puthussery, S, Furmanski, A. Barriers and facilitators to genetic testing for breast and ovarian cancer amongst Black African women in Luton (UK). J Genet Couns. 2023; :. doi: 10.1002/jgc4.1742. PubMed PMID:37403830
2. Abratenko, P, Andrade Aldana, D, Anthony, J, Arellano, L, Asaadi, J, Ashkenazi, A, Balasubramanian, S, Baller, B, Barr, G, Barrow, J et al.. First Measurement of Quasielastic Λ Baryon Production in Muon Antineutrino Interactions in the MicroBooNE Detector. Phys Rev Lett. 2023;130 (23):231802. doi: 10.1103/PhysRevLett.130.231802. PubMed PMID:37354393
3. Eddy, K, Gupta, K, Pelletier, JC, Isola, AL, Marinaro, C, Rasheed, MA, Campagnolo, J, Eddin, MN, Rossi, M, Fateeva, A et al.. A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study. J Invest Dermatol. 2023; :. doi: 10.1016/j.jid.2023.03.1664. PubMed PMID:36997110
4. Abratenko, P, Andrade Aldana, D, Anthony, J, Arellano, L, Asaadi, J, Ashkenazi, A, Balasubramanian, S, Baller, B, Barr, G, Barrow, J et al.. First Constraints on Light Sterile Neutrino Oscillations from Combined Appearance and Disappearance Searches with the MicroBooNE Detector. Phys Rev Lett. 2023;130 (1):011801. doi: 10.1103/PhysRevLett.130.011801. PubMed PMID:36669216
5. Xie, T, Zahid, H, Ali, AR, Joyce, R, Yang, G, Winz, C, Le, Y, Zhou, R, Furmanski, P, Hu, L et al.. Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer. Toxicol Appl Pharmacol. 2023;460 :116375. doi: 10.1016/j.taap.2023.116375. PubMed PMID:36634873 PubMed Central PMC9879264
6. Yánez, DC, Lau, CI, Papaioannou, E, Chawda, MM, Rowell, J, Ross, S, Furmanski, A, Crompton, T. The Pioneer Transcription Factor Foxa2 Modulates T Helper Differentiation to Reduce Mouse Allergic Airway Disease. Front Immunol. 2022;13 :890781. doi: 10.3389/fimmu.2022.890781. PubMed PMID:36003391 PubMed Central PMC9393229
7. Abud, AA, Abi, B, Acciarri, R, Acero, MA, Adames, MR, Adamov, G, Adamowski, M, Adams, D, Adinolfi, M, Aduszkiewicz, A et al.. Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC. Eur Phys J C Part Fields. 2022;82 (7):618. doi: 10.1140/epjc/s10052-022-10549-w. PubMed PMID:35859696 PubMed Central PMC9288420